1. Home
  2. POM vs MBRX Comparison

POM vs MBRX Comparison

Compare POM & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo POMDOCTOR LIMITED American Depositary Shares

POM

POMDOCTOR LIMITED American Depositary Shares

HOLD

Current Price

$0.69

Market Cap

11.3M

ML Signal

HOLD

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

HOLD

Current Price

$0.41

Market Cap

9.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POM
MBRX
Founded
2015
2015
Country
China
United States
Employees
165
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.3M
9.6M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
POM
MBRX
Price
$0.69
$0.41
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$61.00
AVG Volume (30 Days)
55.2K
1.1M
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$0.26
52 Week High
$6.43
$7.98

Technical Indicators

Market Signals
Indicator
POM
MBRX
Relative Strength Index (RSI) 40.50 15.98
Support Level $0.63 N/A
Resistance Level $1.78 $0.57
Average True Range (ATR) 0.19 0.24
MACD -0.08 -0.19
Stochastic Oscillator 15.98 9.67

Price Performance

Historical Comparison
POM
MBRX

About POM POMDOCTOR LIMITED American Depositary Shares

Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of its revenue is derived from the Pharmaceutical supply chain segment.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: